New developments in the treatment of latent tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 12 SUPPL. 2, 2000, Pages

  Chaisson, R E ^a  

^a Center for Tuberculosis Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN;

BCG VACCINATION; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; COST OF ILLNESS; DISEASE CONTROL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MORBIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; SHORT COURSE THERAPY; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

ANTITUBERCULAR AGENTS; GUIDELINES; HIV INFECTIONS; HUMANS; ISONIAZID; MASS SCREENING; TUBERCULOSIS; UNITED STATES; WORLD HEALTH;

EID: 0034520818     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Control strategies for tuberculosis epidemics: New models for old problems
2. Targeted tuberculin testing and treatment of latent tuberculosis infection
3. Will DOTS do it? A reappraisal of tuberculosis control in countries with high prevalence of HIV infection
4. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Proiect
5. Prevention of tuberculosis among tuberculin reactors: Maximizing benefits, minimizing risks
6. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
7. Impact of HIV on tuberculosis in sub-Saharan Africa: A regional perspective
8. The prognosis of a positive tuberculin reaction in childhood and adolescence
9. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana
10. Isoniazid prophylaxis in an underdeveloped area
11. Community isoniazid prophylaxis program in an underdeveloped area of Alaska
12. Eleven years of community-based directly observed therapy for tuberculosis
13. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease
14. The tuberculin skin test
15. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection
16. Comparison between a whole blood y-interferon release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for TB exposure
17. Controlled chemoprophylaxis trials in tuberculosis: A general review
18. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial
19. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
20. Results of a directly-observed intermittent isoniazid preventive therapy program in a shelter for homeless men
21. A randomized, controlled trial of interventions to improve adherence with isoniazid therapy to prevent tuberculosis in injection drug users
22. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis
23. Adherence to isoniazid prophylaxis in the homeless: A randomized controlled trial
24. Treatment of Tuberculosis and tuberculosis infection in adults and children
25. Isoniazid preventive therapy: Retrospect and prospect
26. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic
27. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis
28. Short-course chemoprophylaxis for tuberculosis
29. Experimental shortcourse preventive therapy of tuberculosis with rifampin and pyrazinamide
30. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong
31. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice
32. A trial of three regiments to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
33. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-1 infected persons
34. Twice-weekly tuberculosis preventive therapy in HIV infection in Zambia
35. An international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons
36. Notice to readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis in HIV-infected persons taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors